AI experts expect Deep Bio to succeed in the healthcare industry with its innovative technology

SEOUL, SOUTH KOREA (PRWEB) OCTOBER 21, 2022

Deep Bio, a pioneer in medical AI for digital pathology and cancer diagnostics support software, announced that it has been selected as one of the promising AI startups in the ‘Korea AI Startup 100’ list for the second time in a row.

‘Korea AI Startup 100’, an annual accelerator project cohosted by the Korea Economic Daily and AI One Team, an Industry-University-Research Council, discovers promising Korean AI startups. The project aims to support companies to strengthen their market presence and build their capability, thus enhancing national AI competitiveness in the global market as well as boosting the establishment of the startup ecosystem.

To choose the most notable 100 startups, a committee made up of AI experts evaluated candidates based on criteria that the Korea Advanced Institute of Science and Technology (KAIST) and KT Economics & Management Research Institute developed. The applicants were assessed on both quantitative factors such as market growth potential, corporate value, competitiveness in the AI technology space, and qualitative aspects including corporate sustainability.

After three rounds of evaluation, Deep Bio was selected as one of the finalists of the Korea AI Startup 100 in the healthcare industry. “It is a great honor to be designated as a promising startup that represents Korea. This opportunity once again becomes motivation for our company to advance our AI capability that can contribute to the society,” said Sun Woo Kim, the CEO of Deep Bio. He also added, “with our innovative deep learning technology, we will strive to lead the digitalization of medical care.”